Hot Investor Mandate 3: Global Venture Firm Invests New $400 Million Fund in Novel Therapeutics and Commercial-Stage Medtech

24 Aug

A venture capital firm with offices worldwide closed a new fund in 2017. The firm predominantly focuses on seed and series A and B investments in early stage biotechnology companies, as well as growth equity investments in medical devices companies. The firm’s typical investment size for early stage companies is $5M-$15M and the firm can allocate up to $35-40M total over the life of an investment. The firm focuses on companies that are based in the U.S., Canada and Europe and is actively seeking new investment opportunities.

The firm’s newest fund closed at $400 million, and will invest in 20‐25 biotechnology companies in the U.S., Canada and Europe.

The firm focuses on novel therapeutics and is opportunistic in terms of subsectors and indications. The firm is interested in novel small molecule and biologic therapeutics that address immuno-oncology, orphan/rare or genetic-based diseases, inflammation, infectious diseases and specific viruses, microbiome, and fibrosis and CNS indications. The firm is also interested in regenerative medicine and gene therapy. In medical devices, the firm is generally agnostic to subsector, but is more interested in revenue-generating devices that address cardiovascular, orthopedic, ophthalmic and neurological disorders. Versant prefers devices with proof-of-concept and strong IP.

The firm prefers that a startup company has a strong and experienced management team or technical experts in the relevant technology. The firm generally is flexible with management teams.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: